Market Research Report
Chimeric Antigen Receptor (CAR) T Cell Therapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges
|Published by||DelveInsight Business Research LLP||Product code||740512|
|Published||Content info||605 Pages
Delivery time: 1-2 business days
|Chimeric Antigen Receptor (CAR) T Cell Therapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges|
|Published: November 1, 2018||Content info: 605 Pages||
“Chimeric Antigen Receptor (CAR) T-Cell Therapy- Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges” offers a descriptive overview of the CAR-T Cell Therapy Market industry, which includes: CAR-T therapy global competitive landscape, CAR-T combination therapies, current prominent research areas, key players, geography-wise regulatory requirements (USA and Europe), technological breakthroughs, market trends and dynamics, strategies of key players and cost reduction analysis etc. which would help companies to strengthen their position in the CAR-T Therapy market. The report also offers a comprehensive evaluation of the CAR-T market. The report features a complete qualitative and quantitative assessment by analyzing data gathered from secondary and primary market research (industry analysts and market participants across key points in the industry's value chain).
The report provides an in-depth analysis of key market trends and governing factors along with market attractiveness as per segments. The report also provides the qualitative impact of various market factors on various CAR-T market segments and geographies. The comprehensive insights provided in this report will help the companies in identifying better opportunities. The Report covers the 102 companies with 286 CAR-T therapies, which are active in this field including 35+ leading companies with 71 products targeting more than 28 different antigens and more than 31 different technologies.
The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings etc. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also covers the KOL views on CAR-T Therapy. Additionally, the report covers the comparative analysis of the sales of two approved drugs (Kymriah and Yescarta). Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells. The strategists can gain a detailed insight and devise appropriate strategies to target specific market.